Skip to main content
Premium Trial:

Request an Annual Quote

NephroSant: Mark Capone

Mark Capone has joined the board of directors of NephroSant, a spinout from the University of California, San Francisco that is developing noninvasive testing solutions for kidney health. He is the president and CEO of Precision Medicine Advisors. Before that, he was president and CEO of Myriad Genetics, and prior to that, he held various positions at Eli Lilly. Capone holds a BS in chemical engineering from Penn State University and an MS in chemical engineering and in management from the Massachusetts Institute of Technology.

The Scan

Genetic Ancestry of South America's Indigenous Mapuche Traced

Researchers in Current Biology analyzed genome-wide data from more than five dozen Mapuche individuals to better understand their genetic history.

Study Finds Variants Linked to Diverticular Disease, Presents Polygenic Score

A new study in Cell Genomics reports on more than 150 genetic variants associated with risk of diverticular disease.

Mild, Severe Psoriasis Marked by Different Molecular Features, Spatial Transcriptomic Analysis Finds

A spatial transcriptomics paper in Science Immunology finds differences in cell and signaling pathway activity between mild and severe psoriasis.

ChatGPT Does As Well As Humans Answering Genetics Questions, Study Finds

Researchers in the European Journal of Human Genetics had ChatGPT answer genetics-related questions, finding it was about 68 percent accurate, but sometimes gave different answers to the same question.